Alira Health is a company that supports the entire product lifecycle, from early development of pharmaceuticals and medical devices to clinical trials, regulatory submissions, and market access. The company has particular strengths in CMC (Chemistry, Manufacturing, and Controls) and regulatory strategy, and comprehensively supports companies' development strategies with a patient-centric approach. This page summarizes Alira Health's features and strengths based on our research.
for a Proof of Concept (PoC) toward a new drug candidate,Support for non-clinical study budget planning, design, and schedule development.We will build a strategic approach to pharmacological and toxicological studies based on the requirements of regulatory authorities such as the FDA and EMA, and reduce development risks by providing a roadmap for a smooth transition to subsequent clinical trials.
Since Alira Health does not have a laboratory,Selection of external CDMOs and GLP-compliant CROs suitable for customer needs and development itemsWe will support contract negotiations for master service agreements, provide technical oversight, and manage quality control on behalf of clients, working to ensure that non-clinical trials outsourced to external vendors proceed on schedule.
Instead of completing the planning and execution of non-clinical studies independently, we collaborate with CMC (Chemistry, Manufacturing, and Controls) and regulatory strategy. We oversee the manufacturing of toxicological study lots used in non-clinical studies, and support the development and qualification of analytical methods. The data obtained from study execution,To consistently assist with the creation of application materials for submission to regulatory authorities.The company is doing so.
The official website did not contain information regarding specific external contract research organizations (CROs) or contract development and manufacturing organizations (CDMOs) that Alira Health partners with or handles.
Alira Health's preclinical trial cases were not posted on the official website.
| Address | 1 Grant Street, Suite 400, Framingham, MA 01702, USA |
|---|---|
| Tel | +1-774-777-5255 |
| Website | https://alirahealth.com |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.